

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
July 21, 2015**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Array BioPharma Inc.

File No. 001-16633 - CF# 32496

Array BioPharma Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on May 7, 2015.

Based on representations by Array BioPharma Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

| | |
|--------------|--------------------------|
| Exhibit 10.1 | through May 7, 2025 |
| Exhibit 10.2 | through February 4, 2025 |
| Exhibit 10.3 | through November 3, 2018 |
| Exhibit 10.4 | through May 7, 2025 |
| Exhibit 10.5 | through May 7, 2025 |

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary